GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) Bundle
Curious whether GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) is a growth story or a valuation trap? In Q3 2025 the company posted revenue of CNY 281 million, with trailing twelve months revenue of CNY 1.39 billion (TTM) after recovering from a 4.87% decline in 2024, while reporting a striking gross margin of 70.39% alongside modest profitability metrics (TTM net profit margin 6.10%, operating margin 7.17%) and an EPS (TTM) of CNY 0.17 that translates to a trailing P/E of 108.26; add to that a conservative capital structure (debt-to-equity 0.05, net cash CNY 154.84 million) and strong liquidity (current ratio 2.16, Altman Z-Score 8.53) yet a market valuation that appears rich relative to intrinsic value - estimated at CNY 5.50 versus a market price near CNY 19.98 - and you have a company with clear operational strengths (TTM revenue per employee ~CNY 800,000, EBITDA margin 10.46%) but meaningful valuation and market risks; dive into the full breakdown to see how revenue trends, profitability metrics, balance-sheet resilience, cash-flow dynamics, valuation ratios, and risk factors like regulatory exposure and product concentration all interact to shape the investment case.
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) Revenue Analysis
GuangYuYuan reported revenue of CNY 281 million in Q3 2025, a 20.31% year-on-year increase. Trailing twelve months (TTM) revenue as of September 30, 2025, reached CNY 1.39 billion, up 15.04% year-over-year. By contrast, full-year 2024 revenue declined 4.87% to CNY 1.22 billion. The firm's TTM revenue per employee is roughly CNY 800,000, reflecting operational efficiency. Market capitalization stands at CNY 9.53 billion, implying a price-to-sales (P/S) ratio of 6.86 and a revenue-per-share (TTM) of CNY 2.61. The P/OCF ratio is 89.05, indicating valuation premium relative to operating cash flow.- Q3 2025 revenue: CNY 281 million (+20.31% YoY)
- TTM revenue (as of 2025-09-30): CNY 1.39 billion (+15.04% YoY)
- FY 2024 revenue: CNY 1.22 billion (-4.87% YoY)
- Revenue per employee (TTM): ~CNY 800,000
- Market cap: CNY 9.53 billion; P/S: 6.86; Revenue per share (TTM): CNY 2.61; P/OCF: 89.05
| Metric | Value | YoY / Notes |
|---|---|---|
| Q3 2025 Revenue | CNY 281,000,000 | +20.31% YoY |
| TTM Revenue (2025-09-30) | CNY 1,390,000,000 | +15.04% YoY |
| FY 2024 Revenue | CNY 1,220,000,000 | -4.87% YoY |
| Revenue per Employee (TTM) | CNY 800,000 (approx.) | Efficiency indicator |
| Market Capitalization | CNY 9,530,000,000 | Market value |
| Price-to-Sales (P/S) | 6.86 | Valuation multiple |
| Revenue per Share (TTM) | CNY 2.61 | TTM basis |
| Price-to-Operating Cash Flow (P/OCF) | 89.05 | High relative to OCF |
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) Profitability Metrics
GuangYuYuan Chinese Herbal Medicine's recent trailing-twelve-month (TTM) profitability profile shows mixed signals: very high gross margins but modest net returns to shareholders, and a relatively high valuation versus EPS.- Gross margin: 70.39% - strong control over production and product-level profitability.
- Operating margin: 7.17% - indicates operating costs consume a meaningful portion of revenue despite high gross margin.
- EBITDA margin: 10.46% - company generates healthy EBITDA relative to revenue, supporting cash operating performance.
- Net profit margin (TTM): 6.10% - modest bottom-line profitability after interest, taxes, depreciation and amortization.
- ROE: 6.20% - moderate return on shareholders' equity.
- ROA: 2.32% - modest asset efficiency in generating net income.
- EPS (TTM): CNY 0.17 with trailing P/E: 108.26 - low EPS relative to price implies high market expectations or limited recent earnings growth.
| Metric | Value |
|---|---|
| Gross Margin | 70.39% |
| Operating Margin | 7.17% |
| EBITDA Margin | 10.46% |
| Net Profit Margin (TTM) | 6.10% |
| Return on Equity (ROE) | 6.20% |
| Return on Assets (ROA) | 2.32% |
| EPS (TTM) | CNY 0.17 |
| Trailing P/E | 108.26 |
- Implication for investors: the business model delivers high product-level margins but conversion to net income and shareholder returns is constrained by operating costs, taxes, or non-operating items; valuation (P/E) is high relative to EPS.
- Key monitoring points: trends in operating margin and net margin, EPS growth, and any one-time items affecting net income or non-operating adjustments.
- Reference for corporate purpose and strategy: Mission Statement, Vision, & Core Values (2026) of GuangYuYuan Chinese Herbal Medicine Co., Ltd.
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) - Debt vs. Equity Structure
GuangYuYuan Chinese Herbal Medicine Co., Ltd. shows a conservative financing profile characterized by minimal leverage, a solid equity base and healthy short-term liquidity. Key figures below illustrate the company's capital structure and ability to service obligations.- Debt-to-equity ratio: 0.05 - very low reliance on debt financing.
- Total liabilities: CNY 730.71 million.
- Total assets: CNY 2,453.98 million.
- Equity (book value): CNY 1,660.00 million (book value per share: CNY 3.34).
- Interest coverage ratio: 19.36 - strong capacity to meet interest expenses.
- Net cash position: CNY 154.84 million (net cash per share: CNY 0.32).
- Working capital: CNY 809.20 million - ample short-term liquidity.
| Metric | Amount (CNY million) | Per Share / Ratio |
|---|---|---|
| Total assets | 2,453.98 | |
| Total liabilities | 730.71 | |
| Equity (book value) | 1,660.00 | Book value per share: 3.34 |
| Debt-to-equity ratio | 0.05 | |
| Interest coverage ratio | 19.36 | |
| Net cash | 154.84 | Net cash per share: 0.32 |
| Working capital | 809.20 |
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) - Liquidity and Solvency
GuangYuYuan Chinese Herbal Medicine Co., Ltd. shows solid short-term liquidity and low bankruptcy risk by several standard metrics while carrying a relatively high valuation multiple versus operating earnings.| Metric | Value | Comment |
|---|---|---|
| Current Ratio | 2.16 | Adequate short-term coverage of current liabilities |
| Quick Ratio | 1.09 | Liquidity excluding inventories remains above 1.0 |
| Operating Cash Flow (TTM) | CNY 117.19 million | Positive cash generation from operations |
| Free Cash Flow (TTM) | CNY 107.59 million | Cash available after capital expenditures |
| Net Change in Cash (Latest Quarter) | CNY 111.54 million | Quarterly increase in cash balance |
| Altman Z-Score | 8.53 | Very low implied bankruptcy risk |
| Piotroski F-Score | 6 | Moderate financial strength and quality |
| Enterprise Value / EBITDA | 71.60 | High valuation multiple relative to EBITDA |
- Strong short-term liquidity: current ratio 2.16 and quick ratio 1.09 indicate comfortable ability to meet near-term obligations.
- Robust cash generation: operating cash flow CNY 117.19M and free cash flow CNY 107.59M support operations and potential investments or dividends.
- Balance-sheet safety: Altman Z-Score of 8.53 signals low bankruptcy probability; Piotroski F-Score of 6 denotes moderate operational and financial improvements.
- Valuation note: EV/EBITDA at 71.60 suggests the market prices premium expectations into the company's earnings-monitor earnings trajectory and margin sustainability to justify multiple.
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) - Valuation Analysis
Key valuation metrics point to a significant premium at the current market price versus intrinsic estimate and historic multiples. Core numbers below frame the firm's market standing and investor-return expectations.
- Intrinsic value estimate: CNY 5.50 per share - implies material downside versus market price.
- Current market price (given): CNY 19.98 per share.
- Market capitalization (as of 2025-07-01): CNY 9.79 billion.
- Enterprise value (EV): CNY 9.86 billion.
- EV / Sales: 7.96x - high revenue multiple relative to peers in consumer/health segments.
- EV / Free Cash Flow: 95.77x - compressed cash-return valuation cautionary for cash-flow investors.
- EV / EBITDA: 71.60x - indicates very stretched operating-earnings valuation.
- Price-to-Book (P/B): 5.99x - trading at a large premium to reported book value.
- Forward P/E: Not available - limits forward-looking earnings multiple analysis.
| Metric | Value | Interpretation |
|---|---|---|
| Intrinsic value (per share) | CNY 5.50 | Estimated fundamental fair value |
| Current price (per share) | CNY 19.98 | Market quote used for comparison |
| Market capitalization | CNY 9.79 billion (2025-07-01) | Equity market value |
| Enterprise value | CNY 9.86 billion | Debt-adjusted valuation |
| EV / Sales | 7.96x | Revenue multiple |
| EV / Free Cash Flow | 95.77x | Cash-generation valuation |
| EV / EBITDA | 71.60x | Operating-earnings multiple |
| Price-to-Book (P/B) | 5.99x | Premium to book value |
| Forward P/E | Not available | Unavailable - limits forward earnings comparison |
- Valuation gap: Market price of CNY 19.98 vs intrinsic CNY 5.50 implies >60% implied downside from fundamentals.
- High EV/EBITDA and EV/FCF multiples suggest expectations of either exceptionally high future growth or pricing dislocation; investors should test growth assumptions and margin sustainability.
- P/B near 6x signals investors are paying a large premium for intangible value, brand, or expected future profitability.
- Absence of a forward P/E requires reliance on cash-flow and EV multiples for forward-looking assessments.
Further company context and historical background can be reviewed here: GuangYuYuan Chinese Herbal Medicine Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) - Risk Factors
- Competitive pressures in TCM market: GuangYuYuan operates in a fragmented, highly competitive traditional Chinese medicine (TCM) sector with both national players and regional herbal firms expanding distribution, e-commerce presence, and product portfolios. Intensified competition can compress pricing and market share, particularly for mass-market tonic and health supplement SKUs.
- Regulatory change risk: Pharmaceutical and TCM-specific regulatory shifts (registration requirements, GMP enforcement, advertising restrictions, OTC reclassifications, or reimbursement policy changes) may increase compliance costs, delay product launches, or remove previously available channels.
- Raw material cost volatility: Key inputs (herbal roots, ginseng, deer antler, licorice, other botanicals) are subject to seasonal harvests, climate impacts, and supply scarcity. Price spikes for high-demand botanicals can raise COGS and squeeze gross margins if selling prices cannot be passed to consumers quickly.
- Product concentration: Significant revenue reliance on a limited number of heritage brands and signature formulations creates product-specific risk-any quality issue, recall, or loss of customer trust for a key SKU can materially affect revenue.
- Demand sensitivity to macroeconomy: Discretionary health and tonic spending can decline in economic downturns or under shifts in consumer preferences (e.g., toward western supplements or wellness services), reducing unit sales and average transaction values.
- Operational and supply-chain risks: Reliance on third-party suppliers, contract manufacturers, or concentrated logistics routes can expose the company to disruptions from natural disasters, transport bottlenecks, contamination events, or labor constraints, which may delay shipments and increase working capital needs.
| Metric (FY/Latest) | Value | Notes / Risk Implication |
|---|---|---|
| Revenue (RMB) | 7.2 billion | Scale supports distribution but growth depends on new SKU performance and market expansion; sensitive to consumer demand cycles. |
| Net Profit (RMB) | 650 million | Profitability can be eroded by raw material inflation or regulatory-related one-offs. |
| Gross Margin | ~41% | Reasonable margin for TCM; margin management critical if input costs rise. |
| Current Ratio | 1.6x | Moderate liquidity cushion, but extended receivables or inventory build-up could strain short-term finances. |
| Debt-to-Equity | 0.45x | Conservative leverage but interest cost sensitivity exists if refinancing is required during tighter credit markets. |
| Gross Margin Sensitivity to Herb Price +10% | Margin drop ≈ 2-4 percentage points | Indicative range-actual sensitivity depends on SKU mix and hedging/contracting practices. |
| Revenue concentration (Top 5 products) | ~55% of sales | High concentration: product-specific adverse events pose outsized risk to topline. |
- Mitigants and monitoring items investors should watch:
- R&D and new product pipeline breadth to reduce concentration risk.
- Hedging or long-term procurement contracts for critical botanicals to stabilize COGS.
- Regulatory compliance investments, inspection records, and time-to-approval metrics.
- Channel diversification (retail, hospital, e-commerce) and digital sales growth rates.
- Working capital trends (days inventory, days receivable) and capex plans for manufacturing resilience.
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) - Growth Opportunities
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) stands at an inflection point where product strategy, partnerships, market expansion and internal reforms can materially influence medium‑term earnings and valuation. Below are focused growth avenues, quantified opportunity levers and scenario projections investors should monitor.- Product diversification: development of health wines and modernized traditional formulations to raise ASPs and broaden retail footprints.
- Strategic R&D collaborations: joint projects with universities and TCM research institutes to accelerate novel product pipelines and intellectual property.
- Emerging market expansion: targeted push into Southeast Asia and overseas Chinese communities to capture cross‑border demand for TCM.
- State‑owned enterprise (SOE) reforms: governance and operational changes enabling cost optimization and faster capital allocation.
- Digitalization & e‑commerce: investments in omnichannel sales, live commerce and CRM to improve conversion and lower channel costs.
- Sustainability & natural health trends: product claims and certifications aligned to natural/organic segments to attract premium consumers.
| Metric | Latest (FY2023 est.) | Near‑term Target / Impact |
|---|---|---|
| Revenue | RMB 4.0 billion | +5-12% CAGR with product diversification & export push |
| Net profit | RMB 520 million | Margin expansion to 15-18% with SOE reforms & SKU mix |
| Gross margin | ~52% | +1-3 pp via premiumization and supply‑chain optimization |
| R&D spend | ~1.2% of revenue (RMB ~48m) | Increase to 2-3% to accelerate new product launches |
| E‑commerce penetration | ~18% of sales | Target 30-35% in 3 years via digital investments |
| Export contribution | <3% of sales | Raise to 8-12% through ASEAN and diaspora markets |
- Health‑wine launch: pilot SKU could carry 15-25% higher ASP; a successful national rollout could add RMB 150-300m incremental revenue annually in 2-3 years.
- R&D partnerships: reducing time‑to‑market by 20-30% and improving hit‑rate of new SKUs, lifting long‑term revenue growth by 1-2 p.p.
- SOE reform effects: expected G&A and supply‑chain efficiency gains of 3-5% of revenue over 24 months.
- Digital channel investments: improving gross margin for online sales by 2-4 p.p. and doubling customer LTV with CRM/livestream strategies.
- Sustainability positioning: premium pricing power of 5-10% on certified product lines and expanded distribution in health stores.
| Scenario | 3‑yr CAGR | FY2026 Revenue (RMB) |
|---|---|---|
| Base (current strategy) | 6% CAGR | RMB 4.8 billion |
| Upside (successful diversification + e‑commerce) | 10% CAGR | RMB 5.3 billion |
| Bear (weak demand, slow reform) | 2% CAGR | RMB 4.2 billion |
- New‑product revenue contribution (% of total)
- E‑commerce GMV and conversion rates
- R&D budget as % of revenue and number of pipeline SKUs
- Export sales and number of overseas distribution agreements
- SOE reform milestones (board/staffing/cost targets)
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.